Bicycletx Limited

Bicyclerd Limited

Michael Skynner

Gemma Elizabeth Mudd

Katerine Van Rietschoten

Kevin McDonnell

Paul John Beswick

Liuhong Chen

Gabriela Ivanova-Berndt

Daniel Paul Teufel

Silvia Pavan

David Witty

Sophie Watcham

Amy Brown

Steven Stanway

Ellen Gowans

Peter U Park

Rachid Lani

Michael Rigby

Nicholas Keen

Tom Smith

Tor Svensson

Punit Seth

Frank Narjes

Liudvikas Urbonas

Pavol Zlatoidsky

Lotta Hidestal

James Cooke

Yuliya Demydchuk

Paul Brennan

Mike Rigby

Harvey Che

John Davis

Donatella Di Rienzo

Tom Li Stephen

Rama McCrory

Emma Murphy

Helen Harrison

Emma Mead

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to P-selectin. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are binders of P-selectin. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by a cell adhesion molecule, such as P-selectin, including vaso-occlusive crisis and sickle cell disease-related conditions, cancer, or COVID-19.

Bicyclic peptide ligands specific for P-selectin

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TfR1. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, and multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder through TfR1 mediated delivery of a therapeutic agent.

Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

The invention relates to a method for screening a library of peptide ligands, said library comprising a plurality of polypeptides covalently linked to a molecular scaffold at two or more amino acid residues, comprising the steps of displaying said library of peptide ligands in a genetic display system, wherein the polypeptide comprises two or more reactive groups which form a covalent linkage to the molecular scaffold, and at least one loop which comprises a sequence of amino acids subtended between two of said reactive groups; exposing the peptide ligands to one or more cells which display one or more target molecules on the cell surface; and screening the peptide ligands for binding against the target, and selecting the ligands which bind to the target.

Modification of polypeptides

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to TREM2. The invention also relates to multimeric binding complexes which comprise at least two of said bicyclic peptide ligands. The invention also includes pharmaceutical compositions comprising said peptide ligands and multimeric binding complexes and the use of said peptide ligands, multimeric binding complexes and pharmaceutical compositions in preventing, suppressing or treating a disease or disorder mediated by TREM2.

Bicyclic peptide ligands specific for TREM2

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of thymic stromal lymphopoietin (TSLP). The invention also includes pharmaceutical compositions comprising said peptide ligands and to the use of said peptide ligands in preventing, suppressing or treating a disease or disorder mediated by TSLP.

Bicyclic peptide ligands specific for TSLP

The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which bind to OX40. The invention also relates to multimeric binding complexes of polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold that are functional agonists of OX40. The invention also includes drug conjugates comprising said peptides and complexes, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands, complexes and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by OX40.

Bicyclic peptide ligands specific for OX40

The present invention provides compounds, compositions thereof, and methods of using the same.

Bicyclic peptide ligands and uses thereof

Growing community of inventors

Cambridge, United Kingdom

Michael Skynner